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Respiratory diseases account for about 25% of all pediatric consultations, and 10% of these are for asthma. The
other main pediatric respiratory diseases, in terms of incidence, are bronchiolitis, acute bronchitis and respiratory
infections. Oral corticosteroids, in particular prednisolone, are often used to treat acute respiratory diseases given
their anti-inflammatory effects. However, the efficacy of treatment with oral corticosteroids differs among the
various types of pediatric respiratory diseases. Notably, also the adverse effects of corticosteroid treatment can differ
depending on dosage, duration of treatment and type of corticosteroid administered — a case in point being
growth retardation in long-course treatment. A large body of data has accumulated on this topic. In this article, we
have reviewed the data and guidelines related to the role of oral corticosteroids in the treatment and management
of pediatric bronchiolitis, wheezing, asthma and croup in the attempt to provide guidance for physicians. Also
included is a section on the management of acute respiratory failure in children.
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The burden of acute respiratory diseases in children in Italy
Acute and chronic respiratory diseases represent a global
public health problem because of their increasing preva-
lence and severity worldwide [1]. This can be attributed
to several factors: (i) the significant increase in the
prevalence of early allergen sensitization in childhood;
(ii) the frequent recurrence of viral infections typically
associated with children; and (iii) the increased survival
of extremely preterm and fragile children born with
bronchopulmonary dysplasia. All these factors contrib-
ute to the increased risk of acute manifestations becom-
ing chronic. Also lung function persistently deteriorates
thereby leading to the development of chronic respira-
tory diseases in adulthood.
Epidemiological data on the prevalence of respiratory
diseases are scarce. Reliable data for Italy come from the* Correspondence: renato.cutrera@opbg.net
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(http://creativecommons.org/publicdomain/zeSIDRIA (Italian Studies on Respiratory Disorders in
Childhood and the Environment) study. Conducted on
over 20,000 children 6–7 years old and on 16,000 ado-
lescents in two phases (1994 and 2002), the SIDRIA
study showed a clear increase in the prevalence of
asthma in both groups [2, 3]. A much more recent study
conducted in Rome confirmed these prevalence data in
a population of preschool children (3–5 years old): 15%
of children experienced at least one episode of wheezing,
and 11% had a doctor’s diagnosis of asthma [4]. The
frequency of allergic sensitization in this age group was
already as high as 12%, while, currently, the prevalence
of allergic sensitization abundantly exceeds 30% of the
10–14-year-old population, with peaks exceeding 40%.
All these data confirm, in Italy, the general worldwide
trend of the increasing frequency of allergic sensitization,
which is a major factor in the occurrence of respiratory
diseases, especially asthma.
If data on the prevalence of allergic sensitization in
Italy are scarce, there are no recent data at all about the
impact of acute respiratory diseases on hospital or emer-
gency department admissions. To access numerical data,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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spective chart review of discharges from the Medical
University of South Carolina from 1956 to 1997, the
primary discharge diagnosis of asthma increased 24-fold
in black children versus 5-fold in white children [5]. This
trend confirmed a previous study [6] and was in line
with a subsequent report that similar increases were
taking place in all industrialized countries [7]. The
causes of this increase are several, but the major cause is
undoubtedly allergic sensitization acting synergistically
with viral infections in the development of acute and
chronic respiratory diseases.
Risk factors
Kusel et al. [8] studied a cohort of 263 at-risk children
(at least one parent was atopic) and found that atopic
sensitization within the first 2 years of life was the most
important risk factor for developing asthma at 5 years.
Suffering from more than two episodes of either Rhino-
virus or Respiratory Syncytial Virus infection, or from a
single infection of the lower respiratory tract was accom-
panied by a 7- and a 5-fold greater risk, respectively, of
developing asthma versus their not atopic peers or peers
who developed allergic sensitization later in life. The
COAST study [9] confirmed these observations. In fact,
in 298 at-risk newborns, both univariate and multivariate
analyses showed that the prevalence of asthma at age 14
years was 6-fold higher in subjects who were allergic at
one year of age. Allergic sensitization became a progres-
sively less significant risk factor with increasing age and
was irrelevant in children > 5 years.
Viral infections have been consistently associated
with wheezing (‘viral wheezing’) [10, 11]. More
recently, bacterial infections were found to be signifi-
cantly associated with acute wheeze in young children
(4 weeks–3 years) in a manner similar to viral infec-
tion but independently [12]. In summary, acute severe
lower respiratory infections caused by viruses or bac-
teria in the first years of life are important contribu-
tors to current asthma and persistent wheeze in older
children sensitized in the first 2 years of life.
Emerging data support the hypothesis that priming of
the immune system to allergens may occur even earlier,
namely, during antenatal life. It is well established that
predisposition to produce IgE in response to environmen-
tal stimuli depends on both genetic and environmental
factors. These interactions probably begin in utero and,
through regulatory mechanisms conditioned by the envir-
onment (‘epigenetic mechanisms’), they may influence the
onset, expression and phenotypes of diseases at later ages
or even in adulthood [13]. The hygiene hypothesis [14]
can provide an interpretive key in this context. In fact, our
environment and the air we breathe can be rich or poor in
bacterial endotoxins. Our mucous membranes (nose, lungand intestine) colonized by millions of germs can be rich
or poor in several pathogenic or non-pathogenic species.
Mucosal colonization is the most powerful immunological
factor that can affect immune system function and induce
appropriate immune responses as the need arises (normal
model), or, mainly, IgE-mediated (allergy) or cytotoxic
(chronic/inflammatory autoimmune diseases) inflamma-
tory responses [15–17]. Thus, children born and living in
rural areas, close to stables and animals, suffer less from
asthma and allergies than their urban counterparts, be-
cause in their early years (even in utero) they are exposed
to non-pathogenic stimuli, i.e., environmental endotoxins
[18]. Furthermore, the hygiene hypothesis is in line with
the finding that the offspring of vaccinated mothers have a
‘better’ gut colonization than the offspring of non-
vaccinated mothers thanks to the broader antibody reper-
toire (in terms of titer and repertoire) passively transferred
to them in the last weeks of pregnancy [19]. Finally, it is
clear that breastfeeding may not only play an anti-
inflammatory role, but may also drive microbiota
colonization and mucosal immune maturation [20]. These
processes are all closely integrated and lead to different
‘imprinting’ of the immune system and thus condition the
predisposition to develop diseases, allergic or not.
With the advent of epigenetics, it became clear that our
genetic heritage is in fact plastic and any alterations in-
duced by DNA methylation/demethylation changes can
become permanent and be transmitted to offspring [21].
Attempts to translate these acquisitions in preventive
measures have been disappointing. Containment of indoor
and outdoor pollution improves the clinical course of lung
disease, but impacts little on their frequency [22]. The
high concentration of endotoxins in the environment is
highly protective, but if associated with a high rate of
pollution, its protective effect can be reverted [22]. There-
fore, preventive measures must not be limited to primary
prevention (namely, healthy and not polluted environ-
ments, breastfeeding, a diet rich in vegetables/fruit, and an
intensive and active immunization policy). In fact, inflam-
mation should be treated to halt its progression or chron-
icity. Only strategies based on a broad range of treatment
protocols, including different classes of anti-inflammatory
drugs or immunomodulatory therapies, may result in
disease modification [23].
Herein, we discuss critical issues related to asthma and
to the treatment of the acute respiratory diseases. We do
not address forms of respiratory diseases, such as pneu-
monia, that have a different pathogenic basis and there-
fore require a very specific approach.
Pharmacology of corticosteroids
Anti-inflammatory action
Given their anti-inflammatory effects, glucocorticoids
are among the most frequently prescribed agents in
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been extended to various diseases. Glucocorticoids have
a very broad spectrum of anti-inflammatory activity that
involves both the humoral and cellular systems (Table 1).
They prevent or suppress inflammation in response to
many stimuli including immunological, radiant, mechan-
ical, chemical and infectious stimuli [24].
Mechanism of action
Corticosteroids bind to specific intracellular receptors in
target tissues to regulate the expression of corticosteroid-
responsive genes, thereby changing the levels of proteins
synthesized by target tissues. Given the time required to
modulate gene expression and protein synthesis, most of
the genomically mediated effects of corticosteroids are not
immediate. This is clinically important because the benefi-
cial effects of corticosteroid therapy are manifested with a
certain delay [25]. On the contrary, the effects of cortico-
steroids exerted via a non-genomic mechanism, e.g., via
steroid-selective membrane receptors, are manifested
immediately [25–28].
Pharmacokinetics
All corticosteroids are well absorbed and effective when
delivered by the oral route. Some water-soluble esters of
hydrocortisone and its synthetic congeners can be admin-
istered intravenously to rapidly obtain high concentrationsTable 1 Effects exerted by glucocorticoids on cells, and factors
involved in the inflammatory response
Cells Factors involved in the
inflammatory response
Comments
Macrophages and
monocytes
Cascade of arachidonic
acid (prostaglandins
and leukotrienes)
Mediated by inhibition of
PLA2 and reduced COX-2
expression.
Inflammatory cytokines
(e.g., IL-1,2,4,5,6,11,13)
and TNF-α
Reduced production and
release.
Cytokines exert multiple
effects on inflammation,
e.g., T-cell activation and
stimulation of fibroblast
proliferation.
Endothelial cells ELAM-1 and ICAM-1 ELAM-1 and ICAM-1 are
important for extravasation
of leukocytes into tissues.
Basophils Histamine and LTC4 IgE-dependent release
inhibited by glucocorticoids.
Fibroblasts Arachidonic acid See “Macrophages and
monocytes”. Glucocorticoids
also reduce the proliferation
of fibroblasts.
Lymphocytes Cytokines (IL-1, IL-2,
IL-3, IL-6, TNF-α,
GM-CSF, interferon-γ)
See “Macrophages and
monocytes”.
COX-2 cyclooxygenase-2, ELAM-1 endothelial-leukocyte adhesion molecule-1,
ICAM-1 intercellular adhesion molecule-1, IL interleukin, LTC4 leukotriene C4,
PLA2 phospholipase A2, TNF-α, tumor necrosis factor-αof the drug in body fluids. Glucocorticoids can also be
absorbed systemically from sites of local administration
(i.e., the respiratory tract). After absorption, ≥90% of
plasma cortisol is reversibly bound to proteins. Only the
fraction of free corticosteroid is active and can enter cells.
Two plasma proteins represent almost the entire binding
capacity of steroids: corticosteroid-binding globulin (also
called ‘transcortin’) and albumin. All biologically active
corticosteroids are extensively metabolized in the liver.
Synthetic steroids with an 11-keto group, such as corti-
sone and prednisone, must be enzymatically reduced to
the corresponding 11β-hydroxy derivative to be biologic-
ally active. In conditions in which this enzymatic activity
is deranged, it is advisable to use steroids that do not
require enzymatic activation (i.e., hydrocortisone or pred-
nisolone). Such conditions include severe liver failure,
defects of hexose-6-phosphate dehydrogenase, and the
rare condition of cortisone reductase deficiency [27].
According to the GINA (Global Initiative for Asthma)
Guidelines, oral glucocorticoid administration is as effect-
ive as intravenous administration [29]. However, different
oral formulations may have different pharmacokinetic
profiles; for instance, compared to the tablet formulation,
liquid prednisolone results in significantly higher plasma
concentrations immediately after administration [30].
Moreover, prednisolone solution produces a 20% higher
peak plasma level of prednisolone approximately 15 min
earlier than tablets [31]. The liquid preparation is there-
fore a suitable alternative for children and patients unable
to swallow tablets [30].
Glucocorticoids in medical practice
Attempts have been made to increase the anti-
inflammatory effect of glucocorticoids by modifying their
molecular structure. In many cases, these synthetic
agents exert an enhanced anti-inflammatory effect and
their action is more prolonged. The most widely used
synthetic glucocorticoids in medical practice are listed in
Table 2 [24, 27, 32]. Oral corticosteroids are classified
based on their anti-inflammatory potency, which corre-
sponds to the duration of action, and on the potency of
the suppressive hypothalamic-pituitary-adrenal (HPA)
axis. Equivalent doses of each corticosteroid adminis-
tered in clinical practice are calculated taking into ac-
count the different anti-inflammatory potencies, and
exert the same anti-inflammatory effects. Notably, both
the genomic- and non-genomic effects exerted by the
various types of corticosteroids differ widely in terms of
their relative potencies. For example, betamethasone has
a very low non-genomic potency versus prednisolone
but a higher genomic potency, which suggests that pred-
nisolone has a faster onset of action [26]. These charac-
teristics can serve to define the clinical efficacy/
tolerability profile of each molecule.
Table 2 Classification and comparison of the major systemically used glucocorticoids
Glucocorticoid Equivalent dose (mg) Anti-inflammatory potency* Salt retention* Suppressive HPA potency* Biological half-life (h)
Hydrocortisone 20 1 1 1 8–12 Short
Cortisone 25 0.8 0.8 1 8–12 Short
Prednisolone 5 4 0.8 1 12–36 Intermediate
Prednisone 5 4 0.8 1 12–36 Intermediate
Methylprednisolone 4 4–5 0.2–0.5 5 12–36 Intermediate
Triamcinolone 4 5–10 0 5 12–36 Intermediate
Dexamethasone 0.75 25 0 50 36–72 Long
Betamethasone 0.75 25 0 50 36–72 Long
*Hydrocortisone as reference drug set equal to 1
HPA hypothalamic-pituitary-adrenal axis
Table 3 Signs and symptoms suggestive of adrenal
insufficiency
Cardiovascular instability
Discrepancy between disease severity and clinical status of the
patient presenting nausea
Orthostatic hypotension
Dehydration
Lower abdominal pain or weight loss
Fever of unknown origin
Apathy, depression not related to psychiatric illness
Altered pigmentation, loss of axillary and pubic hair
Hypothyroidism and hypogonadism
Hypoglycemia, hyponatremia and hyperkalemia
Neutropenia and eosinophilia
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The most frequent adverse events of corticosteroids are
mainly associated to the suppression of the HPA axis. Con-
sequently, their use should be carefully evaluated in terms
of the benefit/risk ratio [24]. In children, corticosteroids
have been associated to various adverse effects, mainly in
terms of dosage, type of glucocorticoid and treatment dur-
ation [33]. The most frequently observed adverse reactions
associated with short-course oral corticosteroids are vomit-
ing, behavioral changes, infections and disturbed sleep,
while growth retardation is associated with prolonged
treatment [34]. Repeated short courses of oral prednisone
were not associated with any lasting perturbation in bone
metabolism, bone mineralization, or adrenal function [35].
Withdrawal symptoms
Treatment for 3-6 days with corticosteroids that have a
short or intermediate biological half-life (e.g. prednisol-
one or prednisone) is not associated with withdrawal
complications. Withdrawal syndrome is characterized by
the appearance of non-specific symptoms when pro-
longed corticosteroid treatment is stopped abruptly, and
in very rare cases, also when treatment is discontinued
gradually. The symptoms and the most common signs of
corticosteroid withdrawal are anorexia, nausea, vomiting,
severe asthenia, arthromyalgia, headache, weight loss,
depression and lethargy [24, 27].
Adrenocortical insufficiency
Chronic treatment with systemic corticosteroids (SCs) can
induce suppression of the HPA axis. As a consequence, the
adrenal gland may not be able to produce adequate
amounts of cortisol upon discontinuation of treatment.
This secondary adrenal insufficiency is often overlooked in
non-symptomatic cases. It is important to identify asymp-
tomatic patients because exogenous stress (trauma, illness
or surgery) may precipitate a severe acute hypoadrenal cri-
sis. Corticosteroid administration in the initial stage of
stress can prevent this crisis. The pathogenesis of adrenal
insufficiency secondary to corticosteroid therapy iscomplex. Moreover, it varies from patient to patient and
has not yet been fully clarified, especially in terms of predis-
posing factors. The symptoms and signs of adrenal insuffi-
ciency are non-specific (Table 3) and its diagnosis can be
confirmed with the adrenocorticotropin (ACTH) stimula-
tion test. However, the ACTH test cannot identify the rare
cases of adrenal insufficiency due to central suppression of
the HPA axis. In such cases, a more specific test (the
corticotropin-releasing hormone test) is necessary [24].
Factors favoring suppression of the HPA axis
Suppression of the HPA axis depends on several factors;
an understanding of these factors can help to reduce the
risk of this condition.
The glucocorticoid used
The compounds used to treat patients differ in biological
characteristics and indications. The intrinsic potency
and biological half-life of each compound correlate with
the ability to induce suppression of the HPA axis. The
longer the biological half-life, the more prolonged the
ACTH suppression after a single dose (Table 2). Mul-
tiple daily doses reduce the time required for the HPA
• Glucocorticoids prevent or suppress inflammation in response to
immunological, radiant, mechanical, chemical and infectious stimuli.
• Oral glucocorticoids are well absorbed and effective.
• Glucocorticoids have been associated with adverse effects, mainly in
relation to dosage, type of glucocorticoid and treatment duration.
• Prolonged glucocorticoid treatment can be associated with
suppression of HPA axis function and growth retardation.
• Administration of glucocorticoids with a short or intermediate
biological half-life (e.g., prednisolone or prednisone) for 3–6 days is not
associated with withdrawal symptoms.
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creased risk of suppression of the HPA axis. In routine
practice, preference should be given to synthetic analogs
(prednisone and prednisolone) that have a good balance
between potency and HPA axis-inhibiting effect. Greater
potency and a longer biological half-life (e.g., betametha-
sone and dexamethasone) may result in a stronger inhib-
ition of the HPA axis even after the administration of a
single dose. On the other hand, intermediate compounds
such as prednisolone exert very little and transient sup-
pression of the axis with no negative feedback on either
the pituitary gland or hypothalamus, as shown by the ab-
sence of altered ACTH production [32].
As shown in Table 2, the betamethasone:prednisolone
equivalent dose ratio is 25:4; thus, 5 mg of prednisolone
are required to obtain the same efficacy as 0.75 mg of
betamethasone. However, the inhibitory effect of the
betamethasone:prednisolone ratio on the HPA axis is
50:1; thus 250 mg of prednisolone are required to obtain
an inhibitory potency of 1 mg of betamethasone on the
HPA axis! [36].
The glucocorticoid administration schedule
Endogenous cortisol production peaks early in the
morning and gradually declines until evening. Conse-
quently, evening administration of a corticosteroid
would disrupt the normal ACTH circadian cycle. There-
fore, corticosteroids should be preferably administered
in a single dose in the morning. When, for reasons of
corticosteroid type or for clinical reasons, twice daily
dosing is preferred, two-thirds of the dose may be given
in the morning and one-third in the afternoon. This
administration regime mimics the normal circadian
rhythm of adrenal secretion and decreases the risk of
inhibition of the HPA axis.
Route of administration
The risk of corticosteroid-induced suppression of HPA
axis function is much lower with topical administration
than with oral administration. Inhaled corticosteroids
are generally considered ‘low risk’ and are the first
choice in many diseases (e.g., asthma).
Duration of corticosteroid treatment and cumulative dose
Although epidemiological data are scarce and inconclu-
sive, the duration of corticosteroid treatment and the
cumulative dose are two important risk factors that
predict HPA axis function. From a practical viewpoint,
treatment with prednisolone or prednisone at a dose of
5 mg/day for 10–15 days entails a very low or no risk of
HPA axis inhibition. Obviously, high power and long
biological half-life corticosteroids (betamethasone and
dexamethasone) inhibit the HPA axis in less time.How to reduce the risk of HPA suppression
Although it is difficult to predict HPA suppression in indi-
vidual patients, the following strategies may reduce this risk.
1. Use SCs for well-documented indications.
2. Prefer a medium-acting analog (prednisolone or
prednisone).
3. Use the lowest effective dose for the shortest
duration possible and administer the drug in a single
dose in the morning or, when possible, on alternate
days.
There are no reliable data about the correct way of
discontinuing treatment but only expert opinions and
therapeutic practice established by tradition. Whenever
possible, the corticosteroid dose should be progressively
reduced, and the patient should be monitored for disease
exacerbation, secondary adrenocortical insufficiency, or
withdrawal syndrome.Recovery of the HPA axis
Functional recovery of the HPA axis, especially when ad-
ministering intermediate half-life corticosteroids, can be
obtained by lengthening inter-dose intervals. Where pos-
sible, the compounds with an intermediate potency and
biological half-life (prednisolone and prednisone) should
preferably be administered on alternate days. However,
this strategy has no advantage in case of high potency
compounds and compounds with a long biological half-
life, because they prolong inhibition of the HPA axis.
The time of ’recovery’ of the HPA axis after discontinu-
ing treatment may vary from individual to individual,
and it may take from weeks to months. If the dosage of
steroids is gradually reduced, true adrenal insufficiency
is rare, at least in the absence of stress. There is no dem-
onstration that ACTH treatment can accelerate func-
tional recovery of the HPA axis. Its use for this purpose
is therefore not justified.Summary
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Epidemiology, age frequency and seasonality
Viral bronchiolitis is the most frequent cause of lower
respiratory tract infection and the leading cause of
hospitalization in infants in the first year of life (approxi-
mately 1% of children in Europe and the United States)
[37–40]. The highest age-specific rate of respiratory
syncytial virus (RSV) hospitalization seems to occur in
infants between 30 days and 60 days of age, with con-
trasting rates reported for preterm-born children [38].
The disease is associated with a high mortality rate in
developing countries, but even in industrialized coun-
tries it is the main cause of death due to viral infection
during the first year of life [37]. The most common
pathogen is RSV, which accounts for 60–80% of all cases
[38, 39], with a peak incidence from November to April.
Also human rhinovirus (HRV), parainfluenza virus and
metapneumovirus are frequently involved in bronchio-
litis, with a variable seasonality [37–39].Main risk factors
Severe forms of bronchiolitis requiring hospitalization may
be more frequent in children below 3 months of age (which
corresponds to the natural nadir of postnatal maternal im-
munoglobulins) and in preterm-born children (particularly
those born <32 gestational weeks), whose immune system
is still immature [37, 38, 40]. Infants with such chronic lung
diseases as bronchopulmonary dysplasia and cystic fibrosis,
and those with hemodynamic congenital heart diseases are
also at an increased risk of severe bronchiolitis [37, 38, 40].
Other high risk populations are children with congenital
neuromuscular diseases and with malformation syndromes
or sequences (e.g., Pierre-Robin, CHARGE and Jeune syn-
drome), patients with Down syndrome, because of the
underlying heart disease and their state of relative T
lymphocyte immunodeficiency, and patients with primary
or secondary immunodeficiency (such as Di George or
Wiskott-Aldrich syndrome, neonatal HIV and transplant
recipients) [37]. Finally, male gender, crowding, lack of
breast feeding, low socio-economic status, exposure to in-
door smoke pollution and daycare attendance are also pos-
sible risk factors [38, 40].Clinical presentation and severity
Various definitions of bronchiolitis have been proposed, but
the term is generally applied to a first episode of wheezing
and crackles in infants below 12 months of age [37, 38, 40].
Children with acute bronchiolitis may present with a wide
range of clinical symptoms, therefore a detailed physical
examination and clinical history taking are required [37].
Typically, an infant with bronchiolitis presents during the
epidemic season after 2-4 days of low grade fever, nasal
congestion and rhinorrhea, possibly after exposure topersons with upper respiratory tract viral infection [37–39].
Symptoms of lower respiratory tract illness may include:
 Cough.
 Tachypnea or apnea (especially in preterm infants
below the age of 3 months).
 Increased respiratory effort (grunting, nasal flaring,
and intercostal, subcostal or supraclavicular
retractions).
 Inspiratory crackles and expiratory wheezing at
auscultation.
 Low oxygen saturation (SatO2).
 Dehydration due to feeding difficulties.
In addition, disease severity must be assessed to iden-
tify children who require hospital admission (Table 4).
Management and treatment
The management of bronchiolitis largely depends on the
severity of the condition (Fig. 1). However, the best thera-
peutic approach to the different stages of bronchiolitis is
controversial. Despite the wide array of pharmacological
treatment options, oxygen supplementation and support-
ive therapy to control hydration remain the mainstay of
treatment [37, 38, 40]. Supplemental oxygen should be ad-
ministered if O2 saturation levels are persistently below
90–92% at ambient air [37, 38, 40], with SatO2 measured
by pulse oximetry using pediatric probes and after suc-
tioning of the nares [37, 41]. Oxygen may be administered
by means of nasal prongs or a face mask, but in case of in-
creased respiratory effort, high-flow oxygen therapy with
humidified and heated oxygen (high-flow nasal cannula,
HFNC) should be considered, even in a pediatric ward
setting [37, 41]. Intravenous or nasogastric fluids may be
used for children with bronchiolitis who cannot maintain
oral hydration; the two routes of administration are
similarly effective [37, 38, 40].
Regarding pharmacological therapy, according to the
most recent guidelines and documents on bronchiolitis
management, there is no evidence supporting the use neb-
ulized adrenaline, salbutamol, ipratropium bromide, anti-
biotics, antivirals, or systemic or inhaled corticosteroids in
routine practice [37, 38, 40]. However, hypertonic saline
may be administered in infants to decrease airway edema
and improve mucociliary clearance [38]. Despite evidence
that corticosteroids are beneficial in other respiratory
diseases, large reviews have shown that, in infants with
bronchiolitis, neither systemic nor inhaled steroids
decrease the incidence or duration of hospitalization, nei-
ther do they improve the short- and long-term prognosis
[37, 38, 42]. Several trials have compared the effect of oral
corticosteroids administered for different durations and at
different dosages versus placebo in bronchiolitis manage-
ment [37, 38, 40, 42]. The association of systemic (oral)
Table 4 Factors affecting the decision to admit children to the hospital
Possible discharge Brief observation Hospitalization
Respiratory effort None or mild chest wall retraction Tracheal tug, nasal flare, Moderate
chest wall retraction
Moderate-to-severe respiratory distress,
apnea
Oxygen saturation No supplemental oxygen requirement,
saturations > 95%
Saturations 90–95% Saturations persistently < 90–92%, O2
requirement
Feeding Normal to slightly decreased 50–75% of normal feeds <50% of feeds, unable to feed, dehydration
Gestational age Gestational age >37 weeks, birth
age >12 weeks
Gestational age <37 weeks, birth age <6–12
weeks
Responsivity and
alertness
Reactive, vigilant Less or not responsive
Social factors Good parent compliance, hospital
easily accessible
Non-collaborative parents, Distant from
hospital
Preexisting risk
factors
No risk factors BPD, cystic fibrosis, cyanogenic
congenital heart disease,
immunodeficiency, neuromuscular
disease
BPD, cystic fibrosis, cyanogenic congenital
heart disease, immunodeficiency,
neuromuscular disease
BPD bronchopulmonary dysplasia
Fig. 1 Management of bronchiolitis
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apy has also been evaluated, but according to the National
Institute for Health and Care Excellence [40], corticoste-
roids, whether administered alone or combined with epi-
nephrine or bronchodilator therapy, do not produce a
significant benefit [40]. On the other hand, in a random-
ized trial, oral dexamethasone associated to salbutamol
shortened by a mean of 31% the duration to readiness for
discharge during bronchiolitis episodes in patients with
eczema or with a family history of asthma in a first-degree
relative [43]. Further studies are needed to confirm the lat-
ter finding which was obtained in a selected population of
infants at high risk of asthma.
Environmental and pharmacological prophylaxis
Environmental prophylaxis (with frequent hand washing, and
decontamination of garments, toys and medical instruments)
is necessary to decrease the burden of viral bronchiolitis, es-
pecially in the hospital setting. Pharmacological prophylaxis
with the humanized monoclonal antibody palivizumab for
high risk populations reduces the possibility of developing a
severe form of the disease [37–40, 44]. Given the paucity of
therapeutic alternatives, prevention strategies for RSV infec-
tion are crucial, and on the horizon there are new vaccines
and monoclonal antibodies that have an extended half-life of
70–100 days, and can thus be administered in a single injec-
tion for the whole season. Maternal RSV vaccination is par-
ticularly relevant because hospitalizations peak at 2–3
months of age, when children are unlikely to benefit from ac-
tive immunization. Given the role of RSV in the pathogenesis
of recurrent wheeze and asthma, the importance of monoclo-
nal antibodies and vaccines could extend beyond the preven-
tion of hospital admission of infants to the long-term
respiratory health and primary prevention of asthma [39, 44].
Summary• Bronchiolitis is the most frequent cause of lower respiratory tract
infection in the first year of life, with 60–80% of cases caused by RSV,
and with the highest rate of hospitalization occurring in infants < 2–3
months of age.
• Infants < 3 months old, preterm infants, infants with chronic lung
diseases (bronchopulmonary dysplasia or cystic fibrosis), congenital
heart or neuromuscular diseases, and infants with immunodeficiency
have an enhanced risk of hospitalization.
• Cough, rhinorrhea, low grade fever, tachypnea or apnea, and
symptoms of lower tract respiratory infection (grunting, chest
retractions, crackles and wheezing) may be present.
• Oxygen supplementation and supportive therapy to control hydration
remain the mainstay of treatment.
• There is no evidence supporting the use of salbutamol, nebulized
adrenaline or inhaled or oral corticosteroids in routine practice.
• RSV bronchiolitis, especially when severe, increases the risk of
developing recurrent wheezing and asthma later in life.Wheezing in the preschool child
Given its high prevalence, wheezing in preschool age is a
major issue for pediatricians in terms of diagnosis and
management. It has been suggested that one-third of
preschoolers may present wheezing before the age of
5 years [45] and this condition may be either episodic or
persistent, with different levels of severity. Although pre-
school wheezing usually resolves by school age, and only
a minority of preschool children with wheezing is ex-
pected to develop persistent asthma, most school-age
asthmatic children suffer from wheezing before the age
of six years [3].
Phenotypic classifications
Because of the different clinical and pathophysiological
features of children affected by wheezing, preschool
wheezing is usually approached from a phenotypic per-
spective. In a symptom-based classification of the causal
triggers of wheezing episodes, ‘episodic viral wheezing’
without symptoms between exacerbations was differenti-
ated from ‘multiple-trigger wheeze’ with symptoms be-
tween episodes [46]. In a time-trend-based classification,
childhood wheezing was classified ‘transient wheeze’,
‘persistent wheeze’ or ‘late onset wheeze’ [47]. The ad-
vantage of a phenotypic classification is that patients are
classified according to their basic characteristics in an
early fashion and can thus undergo timely treatment.
However, given the evidence of phenotype instability and
overlapping, it has recently been proposed that wheezing
in preschoolers be classified according to frequency and
severity of symptoms.
Asthma in preschoolers: diagnosis
The 2016 GINA guidelines [29] acknowledged that
asthma may be clinically evident in children below
the age of 5 years. Given that a definite diagnosis of
asthma in preschool children may be complicated by
such confounding factors as recurrent respiratory
tract infections, and given the paucity of tests avail-
able for this age group, the GINA expert panel de-
vised a tentative risk characterization for a diagnosis
of asthma in children focused on symptom severity
and frequency, personal and family characteristics
suggestive of atopy, and response to trial treatment
with inhaled corticosteroids.
Treatment of wheezing in preschoolers
According to the GINA guidelines [29] while short-
acting beta2 agonists are recommended for all asthma
patients when needed, therapeutic strategies in pre-
school children with recurrent wheezing should be
frequently reviewed and be tailored to the characteris-
tics of each child because he/she may be affected by
early asthma as opposed to transient viral wheezing.
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first option in preschool children presenting with re-
current wheezing if episodes are frequent and/or se-
vere, or if interval symptoms are reported [29].
Therefore, while inhaled corticosteroids were previ-
ously administered only in young children who pre-
sented with early signs of asthma, the most recent
position documents recommend inhaled corticoste-
roids also in viral wheezers, either with low-dose
regular treatment or with a high-dose intermittent
strategy [29, 48]. The GINA document [29] confirms
the use of SCs in the treatment of severe exacerba-
tions in children aged 5 years or younger.
Oral corticosteroids are indicated in closely monitored
children with severe exacerbations at a dose equivalent
to prednisolone 1–2 mg/kg/day, with a maximum of
20 mg/day in children below the age of 2 years, and
30 mg/day in children aged 2–5 years. Treatment is rec-
ommended for 3–5 days and can be abruptly halted. The
bitter taste of most oral corticosteroid preparations may
hamper compliance in preschool children. In a group of
78 children, mean age 24 months, with acute asthma ex-
acerbation, oral liquid prednisolone was better tolerated
than crushed tablets administered with lemonade or cus-
tard. It resulted in less vomiting and had a similar level
of efficacy [49]. Although early family/carer-initiated oral
corticosteroids is widely practiced in some countries, the
GINA document questions this practice because of
scarce evidence of its effectiveness in the home manage-
ment of wheezing episodes in preschoolers. Moreover,
the GINA guidelines underline that self-treatment may
be considered only if the physician is confident that
carers are capable of using the medications appropri-
ately, and if the child is closely monitored for side
effects.
The use of SCs, given for decades to treat wheezing in
young children, was based on an extrapolation from
studies conducted in older children and adolescents af-
fected by bronchial asthma who promptly and effectively
responded to treatment with this class of drugs. The re-
sponse to oral corticosteroids may differ depending on
age and on the different phenotypes of wheezing and
asthma in early childhood. In fact, in preschool whee-
zers, airway inflammation is mostly due to a neutrophilic
response to viral triggers, while school-age children
more frequently present with eosinophilic, highly
steroid-responsive airway infiltration [50].
To better address the practical approach to clinical
conditions, a number of studies evaluated the efficacy
of treatment with oral steroids in acute wheezing ex-
acerbations in preschool children. In a study per-
formed in the early nineties in 74 emergency room
children, aged 7–54 months, a single dose of intra-
muscular methylprednisolone in association withinhaled salbutamol was significantly more effective
than placebo in reducing hospitalization [51]. In 2003,
Csonka and coworkers [52] showed that oral prednis-
olone given for 3 days reduced disease severity, length
of hospitalization, and symptom duration in children
aged 6–35 months with virus-induced wheezing. In a
subsequent study of 700 children aged 10 months to
5 years presenting to hospital care for acute virus-
induced wheezing, oral corticosteroids were not better
than placebo for any of the outcomes considered [53].
This study confirmed the authors’ previous observa-
tion obtained in a community-based study that evalu-
ated parent-initiated oral prednisolone administration
for the treatment of virus-induced wheezing in pre-
school children [53]. An editorial accompanying the
latter paper stressed the need to reduce overuse of
oral corticosteroids in preschool children with acute
viral wheezing, but acknowledged that prednisolone
plays a role in the treatment of preschool children
with atopy who have acute exacerbations and in those
with severe episodic wheezing who may be candidates
for admission to an intensive care unit [54].
In 2014, Jartti and coworkers investigated the short-
and long-term efficacy of prednisolone for the first
acute rhinovirus-induced wheezing episode [55]. They
concluded that prednisolone may have a positive ef-
fect in children with a high viral load, although it
cannot be routinely recommended for all young chil-
dren with the first acute rhinovirus-induced wheezing
episode. Very recently, Castro-Rodriguez et al. con-
ducted a meta-analysis of 11 studies devoted to the
role of SCs in preschool children presenting with re-
current exacerbations of wheezing [56]. No difference
was found between oral corticosteroids and placebo
in terms of primary outcomes (hospital admission,
need for an additional course of systemic steroids,
unscheduled visits and length of hospital stay). How-
ever, some studies conducted in emergency depart-
ments suggested a lower risk of hospitalization for
patients treated with oral corticosteroids, and a re-
duced need for additional courses of SCs in the in-
patient setting [56]. In contrast, outpatient children
treated with oral corticosteroids had a higher
hospitalization rate, suggesting that caution be exer-
cised in initiating this treatment in outpatient chil-
dren for whom a risk of more severe exacerbation
cannot be excluded. The authors conclude that oral
corticosteroid treatment may be more effective in
some subgroups of wheezing children, depending on
the severity of exacerbation, timing of administration,
genetic predisposition, underlying inflammatory re-
sponse, and specific viral infection by rhinovirus.
Moreover, they do not consider it appropriate to for-
mulate a broad clinical recommendation for the
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roids and suggest that additional studies with larger,
properly characterized populations be conducted to
address this issue. This concept is echoed by an edi-
torial commenting on the “Dilemma of systemic ste-
roids in preschool children with recurrent wheezing
exacerbations” [57].
In conclusion, in preschool children, treatment with
oral corticosteroids may be beneficial in those with fre-
quent severe exacerbations, mostly those with an atopy
background, and in those requiring emergency depart-
ment or hospital admission and are closely monitored
[29] (Fig. 2), while currently they are not considered to
be indicated in preschool children with mild exacerba-
tion of viral wheeze [48].
Summary• Preschool wheezing is a heterogeneous condition that generally
resolves by school age, but may represent the first manifestation of
asthma in some children.
• It is characterized by different clinical and pathophysiologic features.
• Therapeutic strategies in preschool children with recurrent wheezing
should be tailored to the frequency and severity of clinical
manifestations.
• The evidence supporting early family/carer-initiated oral corticosteroids
in the home management of exacerbations is weak, and this treatment
is not indicated for preschool children with mild exacerbation of viral
wheeze.
• According to the GINA guidelines, oral corticosteroids are indicated in
children with severe wheezing exacerbations.Asthma
Asthma is the most prevalent chronic disease of child-
hood and it results in considerable morbidity. It also in-
terferes with normal activities and causes missed school
days and much parental anxiety. It is characterized by
airway inflammation and hyperresponsiveness to various
stimuli [29, 58, 59]. How these features relate to each
other and contribute to the clinical manifestations of
asthma remains unclear. Important symptoms of asthma
are wheezing, cough, difficulty breathing and chest
tightness.
Management of asthma in the emergency department
Asthma is one of the most common reasons for urgent
care, emergency department visits and hospitalizations.
Emergency department visits and hospitalizations are
due to the severity of the asthma attack, but they are
often due also to the lack of an asthma management
plan or/and insufficient knowledge of how to deal with
worsening on the part of the family. In the SIDRIA-2study [3], the average annual rate of emergency depart-
ment visits of children/adolescents with current asthma
was 10% in the 12 months before study onset. Approxi-
mately 3% of children/adolescents with current asthma
were admitted to hospital in the previous year, and over
30% were hospitalized at least once in their life.
Patients presenting to the emergency department
with an asthma attack should be rapidly evaluated
and triaged to assess the severity of symptoms and
the need for important intervention [60, 61]. The pa-
tient’s history should be carefully collected, and a
physical examination performed. Symptoms are poorly
correlated with the severity of an asthma attack,
therefore it is important to measure, if possible, the
percentage of oxygen saturation (SpO2%) in ambient
air and the peak expiratory flow or forced expiratory
volume in 1 s (FEV1). The partial pressure of carbon
dioxide (PaCO2) should be measured in case of a se-
vere asthma attack. In the emergency department, an
initial assessment should be followed by a second as-
sessment after one hour of treatment to evaluate ac-
curately the severity of the attack (Table 5).
Pharmacological treatment of an asthma attack
Short-acting beta2-agonists
Short-acting beta2-agonists (SABAs) represent the
rescue medication of choice and should be taken as
needed to reverse bronchoconstriction and relieve
symptoms. Salbutamol is the first-line choice. Inhaled
salbutamol should be administered immediately on
presentation. Pressurized metered-dose inhalers
(pMDIs) with holding chambers are the optimal drug
delivery device for patients with asthma exacerbations
[62]. Two to four puffs of salbutamol 100 mcg ad-
ministered by a pMDI via a spacer might be sufficient
for a mild asthma attack, whereas up to 10 puffs may
be needed for more severe attacks, repeated if neces-
sary every 20-30 min during the first hour of treat-
ment, and then every one to four hours as needed.
Children and families must be trained to ensure suc-
cessful delivery of the drug. Inhalers should be
sprayed into the spacer in individual puffs and in-
haled immediately by tidal breathing, for four-five
breaths. If it is not possible to administer SABAs by a
pMDI and spacer, most guidelines recommend the
use of nebulizers at 2.5 mg/dose, up to a maximum
dose of 5 mg, to be repeated every 20–30 min during
the first hour of treatment. SABAs have the same ef-
fects on lung function, rate of hospitalization and
oxygenation irrespective of whether they are delivered
by a pMDI or by a nebulizer. However, bronchodila-
tors delivered by a pMDI result in a shorter stay in
the emergency department and less adverse effects
(tachycardia, palpitation, tremor, and hypokalemia)
Fig. 2 Management of a wheezing episode. Modified from: The Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and
Prevention. 2016
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nebulizers must be used in case of continuous nebuli-
zation (0.5–5 mg/kg/h).
Endovenous administration of salbutamol is recom-
mended in case of a life-threatening acute asthma at-
tack not responsive to inhaled salbutamol. The
recommended regime is 10 mcg/kg in 10 min,
followed by continuous infusion (0.2 mcg/kg/min) up
to a maximum dose of 2 mcg/kg/min. This should be
administered in an intensive care unit with continu-
ous electrocardiogram monitoring and daily electro-
lyte monitoring. Serum potassium levels are often low
after multiple doses of salbutamol and should be
replenished.
Ipratropium bromide
Ipratropium bromide is an anticholinergic agent used,
in addition to inhaled SABAs, to treat children with amoderate-to-severe asthma attack who respond poorly
to SABAs. Repeated doses (250 mcg/dose) of ipratro-
pium bromide should be given. The early addition of
this drug to salbutamol reduces the rate of
hospitalization and improves both FEV1 and the clin-
ical score in 60–120 min. Moreover, it decreases the
rate of nausea and tremor. The addition of ipratro-
pium bromide to salbutamol does not reduce the
duration of hospitalization [63].Epinephrine hydrochloride
Epinephrine hydrochloride remains the drug of choice
in life-threatening situations involving anaphylaxis.
Epinephrine is not recommended for the routine
treatment of an asthma attack. It can be used if in-
haled or intravenous bronchodilators are not
available.
Table 5 Levels of severity of an asthma attack in children
Clinical signs Mild Moderate Severe Life-threatening
Able to talk Able to talk in
sentences
Cannot complete
sentences
Able to pronounce a
few words
-
Respiratory ratea Normal Increased Greatly increased Bradypnea/gasping
Heart rateb Normal Increased Greatly increased Fall in heart rate
Complexion Normal Pallor Pallor/cyanosis Cyanosis
Level of consciousness Normal Restlessness Severe restlessness Obtundation, drowsiness
Wheezing Mild expiratory Expiratory Expiratory/Inspiratory Silent chest
Use of accessory muscles
of respiration
Absent Mild Moderate Paradoxical respiratory movement
SpO2 >95% 92–95% <92% <90%
PaCO2 (mmHg) <38 38–42 >42 >42
Peak expiratory flow >80% 60–80% <60% Not measurable
Not all clinical signs are necessary to classify a given level of severity
aNormal values: at <2 months of age ≤60/min; at 2–12 months ≤50/min; at 1–5 years ≤40/min; at 6–9 years ≤30/min
bNormal values: at 2–12 months of age ≤160/min; at 1–2 years ≤120/min; at 3–8 years, ≤110/min
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Systemic corticosteroids should always be given in case
of an asthma attack, except in patients with a mild at-
tack who rapidly respond to initial therapy with inhaled
SABA. The early use of corticosteroids plays an import-
ant role in the emergency room. The use, versus the
non-use, of corticosteroids is associated with a more
rapid improvement in lung function, fewer hospital ad-
missions, shorter hospitalization, a lower rate of relapse
after discharge from the emergency department, and a
reduction in the need for SABA.
Oral and parenteral corticosteroids are similarly ef-
fective. Nevertheless, the GINA 2016 guidelines rec-
ommend the oral route because it is quicker, less
invasive and less expensive [29]. In the early treat-
ment of acute asthma attacks, international guidelines
[29, 58, 59] recommend oral prednisolone (1-2 mg/
kg/die, up to a maximum dose of 40 mg/die). The
guidelines of the British Thoracic Society underline
that prednisolone is the most widely used steroid in
patients with chronic asthma [59], and there is no
evidence that other steroids provide an advantage [29,
58, 59]. In children, and whenever patients may have
difficulties in swallowing, a liquid formulation is pre-
ferred to tablets [29, 64].
Intravenous methylprednisolone (1-2 mg/kg/6–8 h,
up to a maximum dose of 40 mg) or hydrocortisone
(5–10 mg/kg/6–8 h) should be reserved for severely
affected children who are unable to retain oral medi-
cation. Larger doses do not appear to have a thera-
peutic advantage in most children. Treatment with
intermediate biological half-life oral corticosteroids
(e.g., prednisolone) for up to three-five days is recom-
mended, but treatment should be continued until the
child recovers.High-dose inhaled corticosteroids are associated
with fewer emergency department visits and hospitali-
zations compared with placebo. These drugs are safe
but expensive and their dosage is difficult to establish
[65]. Therefore, there is no evidence supporting the
use of inhaled corticosteroids as a substitute for oral
corticosteroids in the treatment of an asthma attack
[66].Other therapies
Oral or parenteral leukotriene receptor antagonists are
not recommended for the treatment of an asthma attack.
They affect neither function nor the overall
hospitalization rate. Methylxanthines can only be used,
in addition to SABAs, corticosteroids and oxygen ther-
apy, for the treatment of a severe asthma attack. Magne-
sium sulfate may be effective in children with a more
severe asthma attack, however only a few studies have
included children [67]. Heliox is a mixture of helium
and oxygen, usually 70% and 30%, respectively. The role
of heliox in the management of an acute pediatric
asthma attack is unclear.Management of an asthma attack in children aged >
5 years
As shown in the algorithm (Fig. 3), the treatment of
an asthma attack depends on the severity of symp-
toms. There are no criteria on which to predict the
evolution of an asthma attack, and the decision to
hospitalize a child with an asthma attack should be
taken based on the child’s clinical history, symptoms
and lung function.
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• Asthma is one of the most common causes of emergency department
visits.
• Treatment of asthma depends on the severity of the attack.
• The severity of the asthma attack must be rapidly evaluated upon
arrival in the emergency department.
• Short-acting beta2-agonists represent the rescue medication of choice
and should be taken as needed to reverse bronchoconstriction and
relieve symptoms.
• Oral corticosteroids should always be used in case of moderate and
severe asthma attacks since they result in fewer and shorter
hospitalizations.
• According to international guidelines, a liquid formulation of oral
corticosteroids is preferred to tablets in children.Laryngotracheitis in children
Laryngotracheitis, also known as ‘viral croup’, is the most
common and typical form of croup and refers to viral in-
fection of the glottis and subglottic regions [68]. How-
ever, ‘croup’ is a generic term encompassing a
heterogeneous group of childhood respiratory illnesses
affecting the larynx, trachea and bronchi, characterized
by barky cough, stridor, hoarseness and respiratory dis-
tress. These symptoms result from swelling in the area
of the windpipe (trachea) just below the voice box (lar-
ynx). Laryngotracheal airway inflammation induces the
typical symptoms in children because a small decrease
in diameter secondary to mucosal edema and inflamma-
tion exponentially increases airway resistance and the
work of breathing. During inspiration, the walls of the
subglottic space are drawn together thereby producing
the stridor characteristic of croup. Laryngotracheitis,d from: Indinnimeo L et al. Gestione dell’attacco acuto di asma in età
Table 6 Radiological differential diagnosis of croup
Anteroposterior anterior neck radiograph can help to establish an
alternative diagnosis in patients with atypical disease.
• Cone-shaped narrowing instead of the normal squared shoulder
appearance of the subglottic area suggests croup.
• A ragged edge or a membrane spanning the trachea suggests
bacterial tracheitis.
• Thickening of epiglottis and aryepiglottic folds suggest epiglottitis.
• Bulging of the posterior pharynx soft tissue suggests retropharyngeal
abscess.
* Reproduced from: Toward Optimized Practice (TOP) Working Group for
Croup: Guideline for the diagnosis and management of croup. Alberta,
Canada: Edmonton (AB); 2003 (revised 2008). [72]
Cutrera et al. Italian Journal of Pediatrics  (2017) 43:31 Page 14 of 21laryngotracheobronchitis and spasmodic croup are in-
cluded in the croup syndrome [69].
Etiology and epidemiology
The most common causes of laryngotracheitis croup are
parainfluenza viruses (types 1, 2, 3 and 4) and RSV.
Other causative viruses are influenza A and B viruses,
human metapneumovirus and adenovirus [70]. Laryngo-
tracheitis is one of the most frequent causes of acute re-
spiratory distress in young children. The disease is more
common in boys than in girls and mainly affects chil-
dren aged between 6 months and 3 years, with a peak
annual incidence of almost 5% in the second year of life.
However, it can occur in babies as young as 3 months
old and in adolescents [71].
Clinical history
Laryngotracheitis is often mild and self-limiting and re-
solves without any active intervention. However, there
can be significant progressive inflammation and subglot-
ting swelling that may lead to life-threatening airway ob-
struction. Symptom onset is typically abrupt and usually
occurs at night. The child with croup presents a harsh
cough, described as ‘barking’ or ‘brassy’, inspiratory stri-
dor, hoarseness, low grade fever and respiratory distress
that may develop slowly or quickly. Stridor is defined as
the variably pitched noise of breathing associated with a
partially obstructed upper airway. Inspiratory stridor oc-
curs primarily with obstruction of the glottis but also
with subglottic edema. These symptoms are frequently
preceded by non-specific upper respiratory tract symp-
toms 12–48 h before development of the barky cough
and difficulty breathing. Symptoms are generally short-
lived, with resolution of the barky cough within 48 h in
about 60% of children. These symptoms are very often
worse at night, which may be a result of circadian fluctu-
ations in endogenous serum cortisol, the concentrations
of which peak at about 8 am and reach a trough between
11 pm and 4 am [71].
Diagnosis
In the child with classic signs and symptoms, the diag-
nosis of croup is straightforward and can be made based
on the history and physical examination alone. Routine
laboratory tests do not help to establish the diagnosis.
Ancillary testing should be reserved for the rare atypical
presentations. Radiographic studies are rarely indicated
and should be considered in a child in whom the diag-
nosis is unclear or who does not respond as expected to
treatment. Anteroposterior radiographs of the neck can
show the diagnostic subglottic narrowing of croup
known as the ‘steeple sign’. However, radiographs should
be considered only after airway stabilization (Table 6).
According to the guideline developed by the TowardOptimized Practice Program, viral cultures and rapid
antigen tests are not needed to confirm diagnosis [72].
Differential diagnosis
The physician must be aware of other conditions that may
present in a fashion similar to croup, namely, with symp-
toms of stridor and respiratory distress (Table 7). Generally,
it helps to distinguish between infectious (epiglottitis, bac-
terial tracheitis and parapharyngeal abscess) and non-
infectious causes of stridor (foreign body aspiration, allergic
reaction, laryngomalacia, subglottic stenosis, hemangioma,
vascular ring and vocal cord paralysis). It is particularly im-
portant to differentiate a presentation of croup from acute
epiglottitis, which is a medical emergency due to the risk of
sudden airway obstruction.
Traditionally, researchers emphasized differences be-
tween spasmodic croup and laryngotracheitis (viral
croup). Spasmodic croup describes a sudden onset of
croup symptoms, usually at night, but without a signifi-
cant upper respiratory tract prodrome. These episodes
may be recurrent but are usually of short duration. It
has been argued that spasmodic croup might be due to
an allergic reaction to viral antigens rather than to a dir-
ect effect of viral infection [72].
Management and treatment
The most important assessment is the initial evaluation
of croup severity, which is based on assessment of re-
spiratory status and rate, chest wall retractions, stridor,
heart rate, use of accessory muscles and mental status
(Fig. 4). The Westley croup score (WCS) is the most
widely used system with which to evaluate the severity
of this disorder (Table 8). The extent of airway obstruc-
tion is also classified as mild, moderate or severe.
In terms of general care, there is a consensus that chil-
dren with croup should be made as comfortable as possible,
and clinicians should take particular care not to frighten
children during treatment because agitation may greatly
worsen symptoms. The best way to lessen agitation is to
examine and treat the child while he/she is sitting comfort-
ably in the lap of a parent. Oxygen should be administered
Table 7 Main clinical characteristics of laryngotracheitis, epiglottitis, bacterial tracheitis and spasmodic croup
Feature Laryngotracheitis Epiglottitis Bacterial tracheitis Spasmodic croup
Viral prodromal illness ++ - + +
Mean age 6–36 months 3-4 years 4-5 years 6–36 months
Illness onset Gradual Acute Acute Sudden
Fever +/- + + -
Quality of stridor Harsh Mild Harsh Harsh
Drooling, neck hyperextension - ++ + -
Cough ++ - ++ ++
Sore throat +/- ++ +/- -
Recurrence + - - ++
Hospitalization and intubation Rare Frequent Frequent Rare
From: Bell L: Middle respiratory tract infections. In: Pediatric Infectious Diseases: Principle and Practice. Edited by Jenson H, Baltimore R, 2nd edn. Philadelphia:
Saunders; 2002: 772. [98]
Fig. 4 Management of croup. Modified from: TOP Working Group for Croup Guideline for the diagnosis and management of croup. Edmonton
(AB): 2008
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Table 8 Westley croup score
Stridor None: 0
With agitation: +1
At rest: +2
Chest wall retractions None: 0
Mild: +1
Moderate: +2
Severe: +3
Cyanosis None: 0
With agitation: +4
At rest: +5
Level of consciousness Normal: 0
Disoriented: +5
Air entry Normal: 0
Decreased: +1
Markedly decreased: +2
Mild croup (WCS ≤2): occasionally barky cough, no audible stridor at rest, and
no to mild suprasternal and/or intercostal indrawing (retractions of the skin of
the chest wall)
Moderate croup (WCS 3-5): frequent barky cough, easily audible stridor at rest,
and suprasternal and sternal wall retractions at rest, but no or little distress
or agitation
Severe croup (WCS 6-11): frequent barky cough, prominent inspiratory and oc-
casionally expiratory stridor, marked sternal and wall retractions, and signifi-
cant distress and agitation
Impending respiratory failure (WCS >11): barky cough, audible stridor at rest,
sternal and wall retractions, lethargy or decreased level of consciousness and
often dusky appearance without supplemental oxygen
• Laryngotracheitis, also known as ‘viral croup’, is the most common and
typical form of croup, and refers to viral infection of the glottis and
subglottic regions.
• The child with laryngotracheitis presents a harsh cough, described as
‘barking’ or ‘brassy’, inspiratory stridor, hoarseness, low grade fever and
respiratory distress that may develop slowly or quickly.
• Severity can be assessed by the Westley croup score (WCS).
• Anteroposterior radiographs of the neck are rarely indicated and
should be considered in a child in whom the diagnosis is unclear or
who does not respond as expected to treatment.
• Laryngotracheitis is often mild and self-limiting and resolves without
any active intervention.
• Oral corticosteroids are the treatment of choice for children with mild-
to-moderate croup whereas inhaled corticosteroids and nebulized epi-
nephrine are indicated for children with severe respiratory distress.
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children requiring ventilation, see below). Although used
for decades in the acute care setting, humidified air (mist)
is now recognized to be ineffective in croup and should not
be given [73]. Heliox was found to improve clinical croup
scores in some small trials, but there is no evidence of sig-
nificant clinical improvements versus standard treatments
[74]. Similarly, antibiotics, oral decongestants and sedation
are not indicated.
Conventionally, croup is treated with corticosteroids
and epinephrine. The algorithm (Fig. 4) summarizes the
acute management of croup. Corticosteroid therapy ben-
efits patients with croup by decreasing edema in the la-
ryngeal mucosa, and steroids play a part in the
management of croup regardless of severity.
Dexamethasone and prednisolone are the most
commonly used glucocorticoids and are the most ef-
fective for mild-to-moderate croup. Oral corticoste-
roids are well absorbed and reach peak serum
concentrations as rapidly as corticosteroids adminis-
tered intramuscularly (and without pain). Indeed, oral
and intramuscular administration yield equivalent re-
sults [75]. There is no evidence that multiple doses
provide additional benefit over a single dose. Nebu-
lized budesonide is not routinely indicated for the
treatment of croup except in the cases of a child withsevere respiratory distress and of a child who has had
persistent vomiting. In these patients, budesonide may
be mixed with epinephrine and administered
simultaneously.
Nebulized epinephrine causes vasoconstriction of the
subglottic mucosa which reduces edema and swelling. In a
systematic review, the routine use of nebulized epinephrine
was found to provide rapid, short-term relief of severe re-
spiratory distress [76]. The recommended dose is 0.05 mL/
kg (maximal dose 0.5 mL) of racemic epinephrine 2.25%, or
0.5 mL/kg (maximal dose 5 mL) of L-epinephrine 1:1,000
via nebulizer in the clinical setting. Racemic epinephrine
has traditionally been used to treat children with croup.
However, L-epinephrine 1:1,000 is as effective and safe as
the racemate form [76]. The clinical effects of nebulized
epinephrine are sustained for at least 1 h. It is important to
underline that the patient’s symptoms return as the effect
of epinephrine wears off. The administration of nebulized
epinephrine, one dose at a time, in children has not been
associated with such adverse effects as a significant increase
in heart rate or blood pressure [76].
In conclusion, oral corticosteroids are the treatment
of choice for children with croup whereas nebulized
epinephrine is indicated for children with severe re-
spiratory distress. This therapy substantially decreases
intubations, hospital admissions and return visits for
medical care.
SummaryTreatment of acute respiratory failure in children
Acute lower respiratory tract disease (LRTD) is a leading
cause of morbidity and mortality in children < 5 years of
age and, notably, children are more susceptible than
adults to severe manifestations of respiratory diseases,
which in some cases lead to blood oxygen desaturation.
The higher susceptibility of infants may be explained by
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and adults (see Table 9).
Hypoxemia, defined as a decrease in the partial
pressure of oxygen in the blood, can be caused in
LRTD by hypoventilation, ventilation-perfusion mis-
match, right-to-left shunt, diffusion impairment, or
reduced inspired oxygen tension [77]. Hypoxemia as-
sociated with more severe acute LRTDs is a major
criterion for hospitalization and is more common in
young patients.
Respiratory failure is divided into two types:
 Type 1, which is defined as hypoxemia without
hypercapnia. Conditions more often leading to type
1 respiratory failure are characterized by altered
ventilation/perfusion.
 Type 2, which is determined by hypoxia with
hypercapnia. The most frequent causes are increased
airway flow resistance and a decreased surface for
gas exchange.Table 9 Differences in respiratory physiology between children
and adults
Cause Physiological or anatomical basis
Metabolism ↑ O2 consumption ↑
Risk of apnea ↓ Immaturity of control breathing
Airway resistance ↑
Upper airway resistance ↑ Nose breathing
Large tongue
Airway size ↓
Collapsibility ↑
Pharyngeal muscle tone ↓
Compliance of upper airway
structure ↑
Lower airway resistance ↑ Airway size ↓
Collapsibility ↑
Airway wall compliance ↑
Elastic recoil ↓
Lung volume ↓ Numbers of alveoli ↓
Lack of collateral ventilation
Efficiency of respiratory muscles ↓ Efficiency of diaphragm ↓
Rib cage compliance ↑
Horizontal insertion at the rib
cage
Efficiency of intercostal muscles
↓
Horizontal ribs
Endurance of respiratory muscles ↓ Respiratory rate ↑
Fatigue-resistant type I muscle
fibres ↓
From: HammerJ, Eber E (Eds) Paediatric pulmonary function testing. Prog
Respir Res. Basel, Karger, Vol 33, 2005. [99]Management
Hypoxemia and normocapnia
When hypoxemia is the only complication of severe
LRTD and no hypercapnia is identified, administration
of simple oxygen is indicated to maintain blood oxygen
levels. Although, multiple clinical practice guidelines and
protocols recognize that oxygen therapy is an important
component of the treatment of severe acute LRTD [78],
there are no specific guidelines on the correct method of
administering oxygen. Many non-invasive oxygen-
delivery appliances are available; the most frequently
used devices are:
 Face mask. This is connected to an oxygen source
and placed over the patient’s nose and mouth. At
high oxygen flow rates, room air can be entrained
through the small perforations in the mask, whereas
low-flow rates may lead to carbon dioxide retention.
The concentration of oxygen delivered varies de-
pending on two factors: the patient’s respiratory flow
rate and oxygen flow [79]. A face mask interferes
with feeding.
 Hood. This is a transparent plastic box placed
around the infant’s head [80]. It requires high
oxygen flow rates (>5 L/min) to prevent re-
breathing of carbon dioxide [79]. This method en-
ables delivery of a specific fraction of inspired oxy-
gen (FiO2). It limits the infant’s mobility and
interferes with feeding.
 Nasal cannulae or prongs. These devices deliver
oxygen directly into the patient’s nostrils. They can
be either low-flow or high-flow (HFNC) and hu-
midification is required with a flow rate >4 L/min
[81]. In low-flow oxygen treatment, FiO2 varies in
relation to the patient and to the type of prongs, and
it is not possible to determine the amount of FiO2
reaching the patient’s airway [79, 80]. On the con-
trary, with HFNC, the exact amount of FiO2 reach-
ing the airway can be calculated and modulated
irrespective of oxygen flow.
Non-hypercapnic hypoxemia in children with LRTD
has been associated with an increased risk of mortality
and long-term morbidity [82]. Consequently, it is feas-
ible that supplemental oxygen therapy may improve the
outcomes of hypoxemic children presenting with LRTD.
More severely ill patients with significant respiratory
distress, high work of breathing and an enhanced risk of
hypercapnia may benefit from other respiratory methods
of support, namely, HFNC, helmet ventilation or con-
tinuous positive airway pressure (CPAP), which share
the same pathophysiological principle. Continuous
slightly heated humidified air pressure maintains the air-
ways open and prevents alveolar collapsing thereby
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Moreover, heated humidification of the respiratory gas
facilitates secretion clearance. Thanks to these mecha-
nisms, HFNC, helmet ventilation and CPAP improve the
patient’s oxygenation, gas exchange and reduce the work
of breathing, which is important in young children af-
fected by acute respiratory failure.
HFNC consists in the administration of a heated and
humidified mixture of air and oxygen at a flow rate higher
than the patient’s inspiratory flow. Although ‘high-flow’
has yet to be defined, flow rates >2 L/min are generally
considered high in infants, and flow rates >6 L/min are
considered high in children [83]. In clinical practice, some
authors suggest adjusting the oxygen flow rates according
to body weight, and recommend a flow rate of 1 L/kg/min
(max 2 L/kg/min), which provides a degree of distending
pressure [84, 85] and reduces the work of breathing [86].
Oxygen fraction via blender must be frequently adjusted
to maintain target oxygen saturation ≥92. FiO2 can be
gradually weaned when the clinical condition improves as
witnessed by decreased work of breathing and improved
respiratory rate. There is no need to wean flow rate (al-
though this may be considered if flow rates above 1 L/kg/
min have been instituted) [87].
The helmet device, particularly in younger children,
ensures slightly higher pressure values (around 5
cmH2O) compared to HFNC. The helmet, placed
around the patient’s head, must be attached to the pa-
tient by a specific fixing system. Helmets are equipped
with an automatic anti-choking system, and a porthole
that gives airtight access to the patient [88].
CPAP ventilation (pressures vary between 5 and 12 cm
H2O) does not actively assist inspiration; in fact the pa-
tient must sustain the work of breathing. Thus, CPAP
ventilation cannot be considered a true ventilation mode
[89–91]. Continuous positive pressure keeps the airways
open, promotes relaxing of the upper airway dilator
muscles, and reduces the activity of the inspiratory mus-
cles of the upper airways and diaphragm [89, 91].
It is important to stress that the above-described methods
of acute respiratory support should be started only:
 In a pediatric setting in which the patient’s clinical
course can be closely monitored.
 If there is a sufficient number of staff well trained to
recognize the early signs of respiratory failure.
Hypoxemia and hypercapnia
Children with hypercapnic respiratory failure associated
with a poor oxygen-carbon dioxide exchange must be
treated with ventilation. Although it is reasonable to at-
tempt non-invasive ventilation (NIV), young patients
with severe acute respiratory failure that require respira-
tory support might need invasive, positive pressuremechanical ventilation, either conventional or high-
frequency. Invasive ventilation bypasses the patient’s
upper airway with an artificial airway (i.e., an endo-
tracheal tube, a laryngeal mask or tracheostomy tube).
Multiple mechanical ventilation modes are currently
used in clinical practice to provide respiratory support
for a wide spectrum of patients.
As mentioned above, whenever possible and safe, NIV
is the method of choice, as it doesn’t disrupt swallowing,
feeding, speaking or coughing. In pediatric practice, NIV
has reduced the number of children needing intubation
and has also helped to reduce the length of stay in
pediatric intensive care units thanks to the shorter
weaning time versus invasive ventilation [92]. Unlike in-
vasive ventilation, NIV preserves the vocal cords and
trachea, and reduces the risk of infection [93].
The major short-term goals for children with type 2 acute
respiratory failure treated with NIV are to obtain immediate
relief from symptoms, reduce the work of breathing, im-
prove and stabilize gas exchanges, optimize the level of
comfort and avoid intubation [94]. Like oxygen treatment,
NIV can be practiced with various interfaces. The medical
choice depends on the characteristics of the patient (age, fa-
cial characteristics, degree of cooperation and severity of re-
spiratory impairment). Physicians should bear in mind that
the effectiveness of ventilation is inversely correlated to air
leaks [90]. In children, acceptance of the interface is the
first step to successful NIV [95]. Interfaces should have
good adhesion, a low resistance to airflow, be light, exert
the lowest pressure on the skin compatible with effective
ventilation, and the dead space volume should be mini-
mized [96]. Nasal masks are still the most widely used in-
terfaces in children, but oro-nasal and full-face masks are
increasingly being used in many specialized centers [96,
97]. A see-through mask is a good option as it enables the
physician to verify correct positioning of the mask and to
identify complications such as sudden vomiting. Nasal pil-
lows and mouthpieces are other possible options.
As already mentioned, frequent monitoring during NIV
is necessary to ensure the effectiveness and safety of the
procedure. The level and type of monitoring should be
proportional to the patient’s clinical condition [90, 91]. Pa-
tients being treated acutely should be continuously moni-
tored in hospital with a pulse-oximeter or a multichannel
cardio-respiratory monitor. Close clinical observation is
also mandatory and must include assessment of respira-
tory rate and fatigue, level of dyspnea, signs of patient-
ventilator asynchrony, air leaks or short-term complica-
tions of NIV. Side effects of NIV in acute treatment, such
as cutaneous lesions, gastric distension and dry eyes, are
uncommon and described as ‘minor’. Arterial blood gas
analysis should be assessed 1–4 h after the onset of NIV
and 1 h after each change in the ventilator setting or FiO2
concentration [90, 91].
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susceptible than adults to severe manifestations of respiratory diseases,
which in some cases lead to blood oxygen desaturation.
• Hypoxemia associated with severe respiratory diseases is a major
criterion for hospitalization and is more common in young patients.
• Administration of simple oxygen is indicated when hypoxemia is the
only complication and no hypercapnia is present.
• Patients with significant respiratory distress may benefit from HFNC,
helmet ventilation or CPAP. These procedures must be closely
monitored and performed by trained staff.
• If ventilatory support is needed, NIV is the method of choice whenever
possible and safe. It doesn’t disrupt swallowing, feeding, speaking or
coughing, and preserves the vocal cords and trachea. It also reduces
the risk of infection and the length of stay in pediatric intensive care
units.Conclusions
Thanks to their anti-inflammatory action, corticoste-
roids are widely used to treat respiratory diseases in
pediatric practice. However, the decision whether or
not to administer a glucocorticoid in case of acute re-
spiratory disease must be made based on evidence of
efficacy and according to guidelines. There are no
convincing data supporting the use of corticosteroids
to treat bronchiolitis. Oral corticosteroids may be
beneficial in preschool children with severe wheezing
exacerbations that require emergency department or
hospital admission, but currently they are not indi-
cated in preschool children affected by mild exacerba-
tion of viral wheeze. In case of moderate and severe
asthma attacks, all clinical guidelines agree that oral
corticosteroids should be administered since they re-
sult in fewer and shorter hospitalizations. In particu-
lar, guidelines recommend oral prednisolone for the
early treatment of acute asthma exacerbations. Finally,
oral corticosteroids are the treatment of choice for
children with mild-to-moderate croup.
Although corticosteroids exert a beneficial effect on
the course of different acute respiratory diseases in
childhood, the type of corticosteroid to administer and
the appropriate dosage should be carefully evaluated in
order to minimize potential adverse effects.
Abbreviations
ACTH: Adrenocorticotropin; CPAP: Continuous positive airway pressure;
GINA: Global Initiative for Asthma; HFNC: High-flow nasal cannula;
HPA: Hypothalamic-pituitary-adrenal; HRV: Human rhinovirus; LRTD: Lower
respiratory tract disease; NIV: Non-invasive ventilation; RSV: Respiratory
syncytial virus; SABAs: Short-acting beta2-agonists; SC: Systemic
corticosteroids; SIAIP: Italian Society of Pediatric Allergology and
Immunology; SIDRIA: Italian Studies on Respiratory Disorders in Childhood
and the Environment; SIMRI: Italian Society of Pediatric Respiratory Diseases;
TOP: Toward optimized practice; WCS: Westley croup scoreAcknowledgements
This review was produced under the auspices of the Italian Society of
Pediatric Allergology and Immunology (SIAIP) and the Italian Society of
Pediatric Respiratory Diseases (SIMRI). The authors are grateful to Jean Ann
Gilder and Daniela Finizio (Scientific Communication srl, Naples, Italy) for
editing the text.
Funding
This article was supported by Dompé farmaceutici spa through an unrestricted
grant. Cutrera R., Baraldi E., Indinnimeo L., Miraglia Del Giudice M., Piacentini G.,
Scaglione F., Duse M. are members of an Advisory Board supported by an
unrestricted educational grant from Dompé farmaceutici spa.
Availability of data and material
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Authors’ contributions
RC conceived the manuscript, coordinated the writing group and drafted
the Ventilation Section; EB drafted the Bronchiolitis Section; LI drafted the
Asthma Section; MMDG drafted the Croup Section; GP drafted the Wheezing
Section; FS drafted the Pharmacological Section; MD drafted the Burden in
Italy Section; NU, LM and FG performed the literature review and helped to
draft the manuscript. All authors critically reviewed the manuscript and read
and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Pediatric Pulmonology and Sleep & Long Term Ventilation Unit, Academic
Department Pediatric Hospital “Bambino Gesù”, Piazza S. Onofrio 4, 00165
Rome, Italy. 2Women’s and Children’s Health Department, University of
Padua, Via Giustiniani 3, 35128 Padova, Italy. 3Department of Maternal and
Child Care and Urology, Gender Medicine Polyclinic, University of Rome
“Sapienza”, Piazzale Aldo Moro 5, 00185 Rome, Italy. 4Department of Woman,
Child and General and Specialized Surgery, Second University of Naples, Via
Luigi De Crecchio 4, 80138 Naples, Italy. 5Department of Surgery, Dentistry,
Paediatrics and Gynecology, University of Verona, Policlinico G.B. Rossi,
Piazzale L.A. Scuro 10, 37134 Verona, Italy. 6Department of Oncology and
Onco-Hematology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.
Received: 24 December 2016 Accepted: 2 March 2017
References
1. Bousquet J, Burney PG, Zuberbier T, Cauwenberge PV, Akdis CA, Bindslev-
Jensen C, et al. GA2LEN (global allergy and asthma european network)
addresses the allergy and asthma’epidemic’. Allergy. 2009;64:969–77.
2. SIDRIA. Asthma and respiratory symptoms in 6-7 years old Italian children:
gender, latitude, urbanization and socioeconomic factors. SIDRIA (Italian
studies on respiratory disorders in childhood and the environment).
Eur Respir J. 1997;10:1780–6.
3. Sestini P, De Sario M, Bugiani M, Bisanti L, Giannella G, Kaisermann D, et al.
Frequency of asthma and allergies in Italian children and adolescents:
results from SIDRIA-2. Epidemiol Prev. 2005;29:24–31.
4. Indinnimeo L, Porta D, Forastiere F, De Vittori V, De Castro G, Zicari AM,
et al. Prevalence and risk factors for atopic disease in a population of
preschool children in Rome: challenges to early intervention. Int J
Immunopathol Pharmacol. 2016;29:308–19.
Cutrera et al. Italian Journal of Pediatrics  (2017) 43:31 Page 20 of 215. Crater DD, Heise S, Perzanowski M, Herbert R, Morse CG, Hulsey TC, et al.
Asthma hospitalization trends in Charleston, South Carolina, 1956 to 1997:
twenty-fold increase among black children during a 30-year period.
Pediatrics. 2001;108:E97.
6. Mitchell EA. International trends in hospital admission rates for asthma.
Arch Dis Child. 1985;60:376–8.
7. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends
from 1955 to 2004. Thorax. 2007;62:85–90.
8. Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al.
Early-life respiratory viral infections, atopic sensitization, and risk of
subsequent development of persistent asthma. J Allergy Clin Immunol.
2007;119:1105–10.
9. Rubner FJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, et al.
Early life rhinovirus wheezing, allergic sensitization, and asthma risk at
adolescence. 2016;(16)30276–7. Accessed 10 May.
10. Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role
of respiratory viruses in acute upper and lower respiratory tract illness
in the first year of life: a birth cohort study. Pediatr Infect Dis J. 2006;
25:680–6.
11. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al.
Community study of role of viral infections in exacerbations of asthma in
9-11 year old children. BMJ. 1995;310:1225–9.
12. Bisgaard H, Hermansen MN, Bonnelykke K, Stokholm J, Baty F, Skytt NL,
et al. Association of bacteria and viruses with wheezy episodes in young
children: prospective birth cohort study. BMJ. 2010;341:c4978.
13. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy:
multiple suppressor factors at work in immune tolerance to allergens.
J Allergy Clin Immunol. 2014;133:621–31.
14. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–60.
15. von Mutius E. The microbial environment and its influence on asthma
prevention in early life. J Allergy Clin Immunol. 2016;137:680–9.
16. Holt PG. The mechanism or mechanisms driving atopic asthma initiation:
the infant respiratory microbiome moves to center stage. J Allergy Clin
Immunol. 2015;136:15–22.
17. Bach JF. The effect of infections on susceptibility to autoimmune and
allergic diseases. N Engl J Med. 2002;347:911–20.
18. Lynch SV, Wood RA, Boushey H, Bacharier LB, Bloomberg GR, Kattan M, et al.
Effects of early-life exposure to allergens and bacteria on recurrent wheeze
and atopy in urban children. J Allergy Clin Immunol. 2014;134:593–601 e12.
19. Zinkernagel RM. Maternal antibodies, childhood infections, and
autoimmune diseases. N Engl J Med. 2001;345:1331–5.
20. Holt PG, Strickland DH, Sly PD. Virus infection and allergy in the
development of asthma: what is the connection? Curr Opin Allergy Clin
Immunol. 2012;12:151–7.
21. Vercelli D. Does epigenetics play a role in human asthma? Allergol Int. 2016;
65:123–6.
22. D’Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M,
et al. Meteorological conditions, climate change, new emerging factors, and
asthma and related allergic disorders. A statement of the world allergy
organization. World Allergy Organ J. 2015;8:25.
23. Jackson DJ, Gern JE, Lemanske Jr RF. The contributions of allergic
sensitization and respiratory pathogens to asthma inception. J Allergy Clin
Immunol. 2016;137:659–65. quiz 66.
24. Longo D, Fauci D, Hauser S, Jameson J, Loscalzo J. Harrison’s principles of
internal medicine. 18th ed. New York: Mc Graw Hill; 2011.
25. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and
pharmacodynamics of systemically administered glucocorticoids. Clin
Pharmacokinet. 2005;44:61–98.
26. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells.
Steroids. 2002;67:529–34.
27. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s the
pharmacological basis of therapeutics. 12th ed. New York: Mc Graw Hill; 2011.
28. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new
mechanisms for old drugs. N Engl J Med. 2005;353:1711–23.
29. The Global Initiative for Asthma (GINA). Global strategy for asthma
management and prevention. 2016.
30. Georgitis JW, Flesher KA, Szefler SJ. Bioavailability assessment of a liquid
prednisone preparation. J Allergy Clin Immunol. 1982;70:243–7.
31. Dawson KP, Sharpe C. A comparison of the acceptability of prednisolone
tablets and prednisolone sodium phosphate solution in childhood acute
asthma. Aust J Hosp Pharm. 1993;23:320–23.32. Morimoto Y, Oishi T, Hanasaki N, Miyatake A, Noma K, Yamamura Y. Relative
potency in acute and chronic suppressive effects of prednisolone and
betamethasone on the hypothalamic-pituitary-adrenal axis in man.
Endocrinol Jpn. 1980;27:659–66.
33. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-
course oral corticosteroids in children. Arch Dis Child. 2016;101:365–70.
34. Fernandes RM, Oleszczuk M, Woods CR, Rowe BH, Cates CJ, Hartling L. The
Cochrane library and safety of systemic corticosteroids for acute respiratory
conditions in children: an overview of reviews. Evid Based Child Health.
2014;9:733–47.
35. Ducharme FM, Chabot G, Polychronakos C, Glorieux F, Mazer B. Safety
profile of frequent short courses of oral glucocorticoids in acute pediatric
asthma: impact on bone metabolism, bone density, and adrenal function.
Pediatrics. 2003;111:376–83.
36. Le Jeunne C. Pharmacology of glucocorticoids. Presse Med. 2012;41:370–7.
37. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-
society consensus document on treatment and prevention of bronchiolitis
in newborns and infants. Ital J Pediatr. 2014;40:65.
38. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM,
et al. Clinical practice guideline: the diagnosis, management, and
prevention of bronchiolitis. Pediatrics. 2014;134:e1474–502.
39. Mazur NI, Martinon-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T,
et al. Lower respiratory tract infection caused by respiratory syncytial virus:
current management and new therapeutics. Lancet Respir Med. 2015;3:888–900.
40. National Collaborating Centre for Women’s and Children’s Health (UK).
Bronchiolitis: diagnosis and management of bronchiolitis in children.
London: National Institute for Health and Care Excellence (UK); 2015.
41. Moschino L, Mario F, Carraro S, Visentin F, Zanconato S, Baraldi E. Is nasal
suctioning warranted before measuring O2 saturation in infants with
bronchiolitis? Arch Dis Child. 2016;101:114–5.
42. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al.
Glucocorticoids for acute viral bronchiolitis in infants and young children.
Cochrane Database Syst Rev. 2013;6:CD004878.
43. Alansari K, Sakran M, Davidson BL, Ibrahim K, Alrefai M, Zakaria I. Oral
dexamethasone for bronchiolitis: a randomized trial. Pediatrics. 2013;132:
e810–6.
44. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, et al.
Revised recommendations concerning palivizumab prophylaxis for
respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
45. Mallol J, Garcia-Marcos L, Sole D, Brand P. International prevalence of
recurrent wheezing during the first year of life: variability, treatment
patterns and use of health resources. Thorax. 2010;65:1004–9.
46. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A,
et al. Definition, assessment and treatment of wheezing disorders in preschool
children: an evidence-based approach. Eur Respir J. 2008;32:1096–110.
47. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ.
Asthma and wheezing in the first six years of life. The group health medical
associates. N Engl J Med. 1995;332:133–8.
48. Brand PL, Caudri D, Eber E, Gaillard EA, Garcia-Marcos L, Hedlin G, et al.
Classification and pharmacological treatment of preschool wheezing:
changes since 2008. Eur Respir J. 2014;43:1172–7.
49. Lucas-Bouwman ME, Roorda RJ, Jansman FG, Brand PL. Crushed
prednisolone tablets or oral solution for acute asthma? Arch Dis Child. 2001;
84:347–8.
50. Collins AD, Beigelman A. An update on the efficacy of oral corticosteroids in
the treatment of wheezing episodes in preschool children. Ther Adv Respir
Dis. 2014;8:182–90.
51. Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in
infants and toddlers: a controlled clinical trial. Pediatrics. 1990;86:350–6.
52. Csonka P, Kaila M, Laippala P, Iso-Mustajarvi M, Vesikari T, Ashorn P. Oral
prednisolone in the acute management of children age 6 to 35 months
with viral respiratory infection-induced lower airway disease: a randomized,
placebo-controlled trial. J Pediatr. 2003;143:725–30.
53. Panickar J, Lakhanpaul M, Lambert PC, Kenia P, Stephenson T, Smyth A,
et al. Oral prednisolone for preschool children with acute virus-induced
wheezing. N Engl J Med. 2009;360:329–38.
54. Bush A. Practice imperfect–treatment for wheezing in preschoolers. N Engl J
Med. 2009;360:409–10.
55. Jartti T, Nieminen R, Vuorinen T, Lehtinen P, Vahlberg T, Gern J, et al. Short-
and long-term efficacy of prednisolone for first acute rhinovirus-induced
wheezing episode. J Allergy Clin Immunol. 2015;135:691–8 e9.
Cutrera et al. Italian Journal of Pediatrics  (2017) 43:31 Page 21 of 2156. Castro-Rodriguez JA, Beckhaus AA, Forno E. Efficacy of oral corticosteroids in
the treatment of acute wheezing episodes in asthmatic preschoolers:
Systematic review with meta-analysis. Pediatr Pulmonol. 2016;51:868–76.
57. Deshpande DR, Martinez FD. The dilemma of systemic steroids in preschool
children with recurrent wheezing exacerbations. Pediatr Pulmonol. 2016;51:775–7.
58. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and
management of asthma-summary report 2007. J Allergy Clin Immunol.
2007;120:S94–S138.
59. British Thoracic Society. Scottish intercollegiate guidelines network. British
guideline on the management of asthma. Thorax. 2014;69 Suppl 1:1–192.
60. Indinnimeo L, Miraglia Del Giudice M, Chiappini E, Bernardini R, Capristo C,
Cardinale F, et al. Gestione dell’attacco acuto di asma in eta’ pediatrica. In:
Linea guida SIP - aggiornamento 2016. 2016. http://sip.it/wp-content/uploads/
2016/09/LG-SIP-ASMA-ACUTO-Aggiornamento-2016.pdf. Accessed Oct 2016.
61. Castro-Rodriguez JA, Rodrigo GJ, Rodríguez-Martínez CE. Principal findings
of systematic reviews of acute asthma treatment in childhood. J Asthma.
2015;52:1038–45.
62. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers
for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev.
2013;9:CD000052.
63. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-
acting beta2-agonists for initial treatment of acute asthma in children.
Cochrane Database Syst Rev. 2013;8:CD000060.
64. van Asperen PP, Mellis CM, Sly PD, Robertson C. The role of corticosteroids
in the management of childhood asthma: thoracic society of Australia and
New Zealand. 2010.
65. Su XM, Yu N, Kong LF, Kang J. Effectiveness of inhaled corticosteroids in the
treatment of acute asthma in children in the emergency department: a
meta-analysis. Ann Med. 2014;46:24–30.
66. Beckhaus AA, Riutort MC, Castro-Rodriguez JA. Inhaled versus systemic
corticosteroids for acute asthma in children. A systematic review. Pediatr
Pulmonol. 2014;49:326–34.
67. Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, et al. Intravenous and
nebulized magnesium sulfate for treating acute asthma in adults and
children: a systematic review and meta-analysis. Respir Med.
2013;107:321–30.
68. Kliegman RM, Stanton BMD, Geme JS, Schor NF. Nelson textbook of
pediatrics. Philadelphia, PA: Elsevier/Saunders; 2011.
69. Knutson D, Aring A. Viral croup. Am Fam Physician. 2004;69:535–40.
70. Bjornson CL, Johnson DW. Croup in children. Cmaj. 2013;185:1317–23.
71. Bjornson CL, Johnson DW. Croup. Lancet. 2008;371:329–39.
72. Toward Optimized Practice (TOP) Working Group for Croup. Guideline for
the diagnosis and management of croup. Alberta, Canada: Edmonton (AB);
2003 (revised 2008).
73. Moore M, Little P. Humidified air inhalation for treating croup. Cochrane
Database Syst Rev. 2006;19:CD002870.
74. Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care
unit: an evidence-based review. Pediatr Crit Care Med. 2005;6:204–11.
75. Rittichier KK, Ledwith CA. Outpatient treatment of moderate croup with
dexamethasone: intramuscular versus oral dosing. Pediatrics. 2000;106:1344–8.
76. Bjornson C, Russell K, Vandermeer B, Klassen TP, Johnson DW. Nebulized
epinephrine for croup in children. Cochrane Database Syst Rev. 2013;10:
CD006619.
77. Rodriguez-Roisin R, Roca J. Mechanisms of hypoxemia. Intensive Care Med.
2005;31:1017–9.
78. Harris RJ. Transtracheal oxygen therapy success. Chest. 2011;140:563.
79. Frey B, Shann F. Oxygen administration in infants. Arch Dis Child Fetal
Neonatal Ed. 2003;88:F84–8.
80. Myers TR. AARC clinical practice guideline: selection of an oxygen delivery
device for neonatal and pediatric patients–2002 revision & update. Respir
Care. 2002;47:707–16.
81. O’Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen
use in adult patients. Thorax. 2008;63 Suppl 6:vi1–vi68.
82. West TE, Goetghebuer T, Milligan P, Mulholland EK, Weber MW. Long-term
morbidity and mortality following hypoxaemic lower respiratory tract
infection in Gambian children. Bull World Health Organ. 1999;77:144–8.
83. Lee JH, Rehder KJ, Williford L, Cheifetz IM, Turner DA. Use of high flow nasal
cannula in critically ill infants, children, and adults: a critical review of the
literature. Intensive Care Med. 2013;39:247–57.84. Milesi C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, et al.
Is treatment with a high flow nasal cannula effective in acute viral
bronchiolitis? A physiologic study. Intensive Care Med. 2013;39:1088–94.
85. Mayfield S, Bogossian F, O’Malley L, Schibler A. High-flow nasal cannula
oxygen therapy for infants with bronchiolitis: pilot study. J Paediatr Child
Health. 2014;50:373–8.
86. Pham TM, O’Malley L, Mayfield S, Martin S, Schibler A. The effect of high
flow nasal cannula therapy on the work of breathing in infants with
bronchiolitis. Pediatr Pulmonol. 2015;50:713–20.
87. Milesi C, Boubal M, Jacquot A, Baleine J, Durand S, Odena MP, et al.
High-flow nasal cannula: recommendations for daily practice in pediatrics.
Ann Intensive Care. 2014;4:29.
88. Mayordomo-Colunga J, Medina A, Rey C, Concha A, Los Arcos M, Menendez
S. Helmet-delivered continuous positive airway pressure with heliox in
respiratory syncytial virus bronchiolitis. Acta Paediatr. 2010;99:308–11.
89. Boldrini R, Fasano L, Nava S. Noninvasive mechanical ventilation.
Curr Opin Crit Care. 2012;18:48–53.
90. British Thoracic Society Standards of Care Committee. Non-invasive
ventilation in acute respiratory failure. Thorax. 2002;57:192–211.
91. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med. 2001;
163:540–77.
92. Girault C, Briel A, Hellot MF, Tamion F, Woinet D, Leroy J, et al. Noninvasive
mechanical ventilation in clinical practice: a 2-year experience in a medical
intensive care unit. Crit Care Med. 2003;31:552–9.
93. Girou E, Schortgen F, Delclaux C, Brun-Buisson C, Blot F, Lefort Y, et al.
Association of noninvasive ventilation with nosocomial infections and
survival in critically ill patients. Jama. 2000;284:2361–7.
94. Pavone M, Verrillo E, Caldarelli V, Ullmann N, Cutrera R. Non-invasive positive
pressure ventilation in children. Early Hum Dev. 2013;89 Suppl 3:S25–31.
95. Elliott MW. Non-invasive ventilation for acute respiratory disease. Br Med
Bull. 2004;72:83–97.
96. Teague WG. Non-invasive positive pressure ventilation: current status in
paediatric patients. Paediatr Respir Rev. 2005;6:52–60.
97. Fauroux B, Boffa C, Desguerre I, Estournet B, Trang H. Long-term
noninvasive mechanical ventilation for children at home: a national survey.
Pediatr Pulmonol. 2003;35:119–25.
98. Bell L. Middle respiratory tract infections. In: Jenson H, Baltimore R, editors.
Pediatric infectious diseases: principle and practice. 2nd ed. Philadelphia:
Saunders; 2002. p. 772.
99. Hammer J, Eber E. Paediatric pulmonary function testing. Basel: Karger; 2005.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
